Skip to main content
Erschienen in: Annals of Surgical Oncology 12/2009

01.12.2009 | Bone and Soft Tissue Sarcomas

Hyperthermic Isolated Limb Perfusion in Locally Advanced Soft Tissue Sarcoma and Progressive Desmoid-Type Fibromatosis with TNF 1 mg and Melphalan (T1-M HILP) Is Safe and Efficient

verfasst von: Sylvie Bonvalot, MD, PhD, Françoise Rimareix, MD, Sylvain Causeret, MD, Cécile Le Péchoux, MD, Bérénice Boulet, MD, Philippe Terrier, MD, Axel Le Cesne, MD, Jane Muret, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

In a prior randomized phase II trial comparing hyperthermic isolated limb perfusion (HILP) with four different doses of tumor necrosis factor alpha (TNF-α), no dose effect was detected for response, but systemic toxicity was far lower with low-dose TNF-α. The objective of the present study was to confirm these data on a larger sample size of locally advanced or recurrent extremity soft tissue sarcomas with low-dose TNF-α.

Methods

We assessed a prospective database comprising 100 HILP (38–40°C) with melphalan (10 mg/L) and TNF-α (1 mg). The remnant tumor was resected 2 months later.

Results

Among 52 recurrences, 18 were in a previously irradiated field. Stages according to the American Joint Committee on Cancer classification were II (19 patients), III (78 patients), and IV (3 patients). The site/size were: 30 patients/57 mm and 70 patients/86 mm for the upper and lower limbs, respectively. Tumor grades (FNCLCC) were 1 (23 patients), 2 (34 patients), and 3 (43 patients). Fifty-one patients had received systemic chemotherapy before HILP. Responses on magnetic resonance imaging were 30% complete, 49% partial, 9% no change, and 12% progression. No mortality or systemic toxicity occurred. Local toxicity (Wieberdink) attained grade 2 (16 patients), 3 (5 patients), and 4 (1 patient). Limbs were able to be saved in 87% patients. Three-year overall survival and the local recurrence rate were 89% and 18%, respectively. Age, sex, tumor size, recurrence, uni- or multifocality, grade, preoperative chemotherapy, and a previously irradiated field were not predictive of response or local toxicity.

Conclusions

We confirm that 1 mg of TNF-α is as effective as the standard dose and results in no systemic toxicity.
Literatur
1.
Zurück zum Zitat Pisters PW, O’Sullivan B, Maki RG. Evidence-based recommendations for local therapy for soft tissue sarcomas. J Clin Oncol. 2007;25:1003–8.CrossRefPubMed Pisters PW, O’Sullivan B, Maki RG. Evidence-based recommendations for local therapy for soft tissue sarcomas. J Clin Oncol. 2007;25:1003–8.CrossRefPubMed
2.
Zurück zum Zitat Williard WC, Hajdu SI, Casper ES, Brennan MF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg. 1992;215:269–7. Williard WC, Hajdu SI, Casper ES, Brennan MF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg. 1992;215:269–7.
3.
Zurück zum Zitat Eggermont AM. Isolated limb perfusion in the management of locally advanced extremity soft tissue sarcoma. Surg Oncol Clin N Am. 2003;12:469–83.CrossRefPubMed Eggermont AM. Isolated limb perfusion in the management of locally advanced extremity soft tissue sarcoma. Surg Oncol Clin N Am. 2003;12:469–83.CrossRefPubMed
4.
Zurück zum Zitat Creech O, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616–32.CrossRefPubMed Creech O, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616–32.CrossRefPubMed
5.
Zurück zum Zitat Lienard D, Eggermont AM, Kroon BB, Schraffordt Koops H, Lejeune FJ. Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin Surg Oncol. 1998;14:202–9.CrossRefPubMed Lienard D, Eggermont AM, Kroon BB, Schraffordt Koops H, Lejeune FJ. Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin Surg Oncol. 1998;14:202–9.CrossRefPubMed
6.
Zurück zum Zitat Grünhagen DJ, de Wilt JH, van Geel AN, Eggermont AM. Isolated limb perfusion for melanoma patients: a review of its indications and the role of tumour necrosis factor-alpha. Eur J Surg Oncol. 2006;32:371–80.CrossRefPubMed Grünhagen DJ, de Wilt JH, van Geel AN, Eggermont AM. Isolated limb perfusion for melanoma patients: a review of its indications and the role of tumour necrosis factor-alpha. Eur J Surg Oncol. 2006;32:371–80.CrossRefPubMed
7.
Zurück zum Zitat Eggermont AM. TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectives. Anticancer Res. 1998;18(5D):3899–905.PubMed Eggermont AM. TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectives. Anticancer Res. 1998;18(5D):3899–905.PubMed
8.
Zurück zum Zitat Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10:52–60.PubMed Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10:52–60.PubMed
9.
Zurück zum Zitat Menon C, Ghartey A, Canter R, Feldman M, Fraker DL. Tumor necrosis factor-alpha damages tumor blood vessel integrity by targeting VE-cadherin. Ann Surg. 2006;244:781–91.CrossRefPubMed Menon C, Ghartey A, Canter R, Feldman M, Fraker DL. Tumor necrosis factor-alpha damages tumor blood vessel integrity by targeting VE-cadherin. Ann Surg. 2006;244:781–91.CrossRefPubMed
10.
Zurück zum Zitat Creagan ET, Kovach JS, Moertel CG, Frytak S, Kvols LK. A phase I clinical trial of recombinant human tumor necrosis factor. Cancer. 1988;62:2467–71.CrossRef Creagan ET, Kovach JS, Moertel CG, Frytak S, Kvols LK. A phase I clinical trial of recombinant human tumor necrosis factor. Cancer. 1988;62:2467–71.CrossRef
11.
Zurück zum Zitat Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996;224:756–64.CrossRefPubMed Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996;224:756–64.CrossRefPubMed
12.
Zurück zum Zitat Laurenzi L, Natoli S, Di Filippo F, et al. Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha. J Exp Clin Cancer Res. 2004;23:225–31.PubMed Laurenzi L, Natoli S, Di Filippo F, et al. Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha. J Exp Clin Cancer Res. 2004;23:225–31.PubMed
13.
Zurück zum Zitat Vrouenraets BC, Kroon BB, Ogilvie AC, et al. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol. 1999;6:405–12.CrossRefPubMed Vrouenraets BC, Kroon BB, Ogilvie AC, et al. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol. 1999;6:405–12.CrossRefPubMed
14.
Zurück zum Zitat Grünhagen DJ, de Wilt JH, van Geel AN, et al. TNF dose reduction in isolated limb perfusion. Eur J Surg Oncol. 2005;31:1011–9.CrossRefPubMed Grünhagen DJ, de Wilt JH, van Geel AN, et al. TNF dose reduction in isolated limb perfusion. Eur J Surg Oncol. 2005;31:1011–9.CrossRefPubMed
15.
Zurück zum Zitat Bonvalot S, Laplanche A, Lejeune F, et al. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-α be better? Ann Oncol. 2005;16:1061–8.CrossRefPubMed Bonvalot S, Laplanche A, Lejeune F, et al. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-α be better? Ann Oncol. 2005;16:1061–8.CrossRefPubMed
16.
Zurück zum Zitat Trojani M, Contesso G, Coindre JM, et al. Soft tissue sarcoma of adults, study of pathological variables and definition of histopathological grading system. Int J Cancer. 1984;33:37–42.CrossRefPubMed Trojani M, Contesso G, Coindre JM, et al. Soft tissue sarcoma of adults, study of pathological variables and definition of histopathological grading system. Int J Cancer. 1984;33:37–42.CrossRefPubMed
17.
Zurück zum Zitat Grunhagen DJ, de Wilt JH, Graveland WJ, et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer. 2006;106:1776–84.CrossRefPubMed Grunhagen DJ, de Wilt JH, Graveland WJ, et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer. 2006;106:1776–84.CrossRefPubMed
18.
Zurück zum Zitat Fiore M, Rimareix F, Mariani L, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16:2587–93.CrossRefPubMed Fiore M, Rimareix F, Mariani L, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16:2587–93.CrossRefPubMed
19.
Zurück zum Zitat Bonvalot S, Eldweny H, Haddad V, et al. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol. 2008;34:462–8.PubMed Bonvalot S, Eldweny H, Haddad V, et al. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol. 2008;34:462–8.PubMed
20.
Zurück zum Zitat Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer Institute of the United States, National Cancer Insitute of Canada. J Natl Cancer Inst. 2000;92:205–6.CrossRefPubMed Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer Institute of the United States, National Cancer Insitute of Canada. J Natl Cancer Inst. 2000;92:205–6.CrossRefPubMed
21.
Zurück zum Zitat Baumert BG, Spahr MO, Von Hochstetter A, et al. The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the Rare Cancer Network. Radiat Oncol. 2007;2:12. Baumert BG, Spahr MO, Von Hochstetter A, et al. The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the Rare Cancer Network. Radiat Oncol. 2007;2:12.
22.
Zurück zum Zitat Thompson JF, Lai DT, Ingvar C, Kam PC. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res. 1994;4(Suppl 1):45–50.PubMed Thompson JF, Lai DT, Ingvar C, Kam PC. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res. 1994;4(Suppl 1):45–50.PubMed
23.
Zurück zum Zitat Vanel D, Bonvalot S, Guinebretiere JM, et al. MR imaging in the evaluation of isolated limb perfusion: a prospective study of 18 cases. Skeletal Radiol. 2004;33:150–6.CrossRefPubMed Vanel D, Bonvalot S, Guinebretiere JM, et al. MR imaging in the evaluation of isolated limb perfusion: a prospective study of 18 cases. Skeletal Radiol. 2004;33:150–6.CrossRefPubMed
24.
Zurück zum Zitat Tumor of bone and soft tissues. R classification. In Sobin LH, Wittekind Ch, eds. TNM Classification of Malignant Tumours, UICC. 6th ed. New York: Wiley Liss, 2002:110. Tumor of bone and soft tissues. R classification. In Sobin LH, Wittekind Ch, eds. TNM Classification of Malignant Tumours, UICC. 6th ed. New York: Wiley Liss, 2002:110.
25.
Zurück zum Zitat World Health Organization (WHO). WHO Handbook for Reporting Results of Cancer Treatment. Publication 48. Geneva: WHO, 1979. World Health Organization (WHO). WHO Handbook for Reporting Results of Cancer Treatment. Publication 48. Geneva: WHO, 1979.
26.
Zurück zum Zitat Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18:905–10.CrossRefPubMed Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18:905–10.CrossRefPubMed
27.
Zurück zum Zitat Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Statist Assn. 1958;53:457–81.CrossRef Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Statist Assn. 1958;53:457–81.CrossRef
28.
Zurück zum Zitat Rothman KJ. Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chronic Dis. 1978;31:557–60.CrossRefPubMed Rothman KJ. Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chronic Dis. 1978;31:557–60.CrossRefPubMed
29.
Zurück zum Zitat Schemper M, Smith T. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–6.CrossRefPubMed Schemper M, Smith T. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–6.CrossRefPubMed
30.
Zurück zum Zitat Gutman M, Inbar M, Lev-Shlush D, et al. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer. 1997;79:1129–37.CrossRefPubMed Gutman M, Inbar M, Lev-Shlush D, et al. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer. 1997;79:1129–37.CrossRefPubMed
31.
Zurück zum Zitat Cherix S, Speiser M, Matter M, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients. J Surg Oncol. 2008;98:148–55.CrossRefPubMed Cherix S, Speiser M, Matter M, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients. J Surg Oncol. 2008;98:148–55.CrossRefPubMed
32.
Zurück zum Zitat Pennacchioli E, Deraco M, Mariani L, et al. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann Surg Oncol. 2007;14:553–9.CrossRefPubMed Pennacchioli E, Deraco M, Mariani L, et al. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann Surg Oncol. 2007;14:553–9.CrossRefPubMed
33.
Zurück zum Zitat Nachmany I, Subhi A, Meller I, et al. Efficacy of high vs low dose TNF-isolated limb perfusion for locally advanced soft tissue sarcoma. Eur J Surg Oncol. 2009;35:209–14.PubMed Nachmany I, Subhi A, Meller I, et al. Efficacy of high vs low dose TNF-isolated limb perfusion for locally advanced soft tissue sarcoma. Eur J Surg Oncol. 2009;35:209–14.PubMed
34.
Zurück zum Zitat Eilber FC, Rosen G, Eckardt J, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol. 2001;19:3203–9.PubMed Eilber FC, Rosen G, Eckardt J, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol. 2001;19:3203–9.PubMed
35.
Zurück zum Zitat Sigurdsson GH, Nachbur B, Lejeune F. Anesthesiologist’s management of isolated limb perfusion with “high” doses TNFa. Anesthesiology. 1993;79:1433–7.CrossRefPubMed Sigurdsson GH, Nachbur B, Lejeune F. Anesthesiologist’s management of isolated limb perfusion with “high” doses TNFa. Anesthesiology. 1993;79:1433–7.CrossRefPubMed
36.
Zurück zum Zitat Lans TE, Grünhagen DJ, de Wilt JH, van Geel AN, Eggermont AM. Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs. Ann Surg Oncol. 2005;12:406–11.CrossRefPubMed Lans TE, Grünhagen DJ, de Wilt JH, van Geel AN, Eggermont AM. Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs. Ann Surg Oncol. 2005;12:406–11.CrossRefPubMed
37.
Zurück zum Zitat Lev-Chelouche D, Abu-Abeid S, Nakache R, et al. Limb desmoid tumors: a possible role for isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Surgery. 1999;126:963–7.CrossRefPubMed Lev-Chelouche D, Abu-Abeid S, Nakache R, et al. Limb desmoid tumors: a possible role for isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Surgery. 1999;126:963–7.CrossRefPubMed
38.
Zurück zum Zitat Van Etten B, Van Geel AN, De Wilt JH, Eggermont AM. Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol. 2003;10:32–7.CrossRefPubMed Van Etten B, Van Geel AN, De Wilt JH, Eggermont AM. Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol. 2003;10:32–7.CrossRefPubMed
39.
Zurück zum Zitat O’Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235–41.CrossRefPubMed O’Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235–41.CrossRefPubMed
40.
Zurück zum Zitat Olieman AF, Pras E, van Ginkel RJ, et al. Feasibility and efficacy ofexternal beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys. 1998;40:807–14.CrossRefPubMed Olieman AF, Pras E, van Ginkel RJ, et al. Feasibility and efficacy ofexternal beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys. 1998;40:807–14.CrossRefPubMed
41.
Zurück zum Zitat Vrouenraets BC, Keus RB, Nieweg OE, Kroon BB. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/− interferon gamma and melphalan in patients with irresectable soft tissue tumors. J Surg Oncol. 1997;65:88–94.CrossRefPubMed Vrouenraets BC, Keus RB, Nieweg OE, Kroon BB. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/− interferon gamma and melphalan in patients with irresectable soft tissue tumors. J Surg Oncol. 1997;65:88–94.CrossRefPubMed
42.
Zurück zum Zitat Hoven-Gondrie ML, Thijssens KM, Van den Dungen JJ, et al. Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity. Ann Surg Oncol. 2007;14:2105–12.CrossRefPubMed Hoven-Gondrie ML, Thijssens KM, Van den Dungen JJ, et al. Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity. Ann Surg Oncol. 2007;14:2105–12.CrossRefPubMed
43.
Zurück zum Zitat Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14:1679–89.PubMed Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14:1679–89.PubMed
44.
Zurück zum Zitat Stojadinovic A, Jaques DP, Leung DH, Healey JH, Brennan MF. Amputation for recurrent soft tissue sarcoma of the extremity: indications and outcome. Ann Surg Oncol. 2001;8:509–18.CrossRefPubMed Stojadinovic A, Jaques DP, Leung DH, Healey JH, Brennan MF. Amputation for recurrent soft tissue sarcoma of the extremity: indications and outcome. Ann Surg Oncol. 2001;8:509–18.CrossRefPubMed
45.
Zurück zum Zitat Muret J, Yacoub M, Terrier P, et al. p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-alpha and melphalan. Ann Oncol. 2008;19:793–800.CrossRefPubMed Muret J, Yacoub M, Terrier P, et al. p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-alpha and melphalan. Ann Oncol. 2008;19:793–800.CrossRefPubMed
46.
Zurück zum Zitat Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol. 1998;14:238–47.CrossRefPubMed Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol. 1998;14:238–47.CrossRefPubMed
47.
Zurück zum Zitat Möller MG, Lewis JM, Dessureault S, Zager JS. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperthermia. 2008;24:275–89.CrossRefPubMed Möller MG, Lewis JM, Dessureault S, Zager JS. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperthermia. 2008;24:275–89.CrossRefPubMed
48.
Zurück zum Zitat Moncrieff MD, Kroon HM, Kam PC, Stalley PD, Scolyer RA, Thompson JF. Isolated limb infusion for advanced soft tissue sarcoma of the extremity. Ann Surg Oncol. 2008;15:2749–56.CrossRefPubMed Moncrieff MD, Kroon HM, Kam PC, Stalley PD, Scolyer RA, Thompson JF. Isolated limb infusion for advanced soft tissue sarcoma of the extremity. Ann Surg Oncol. 2008;15:2749–56.CrossRefPubMed
49.
Zurück zum Zitat Brady MS, Brown K, Patel A, Fisher C, Marx W. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol. 2006;13:1123–9.CrossRefPubMed Brady MS, Brown K, Patel A, Fisher C, Marx W. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol. 2006;13:1123–9.CrossRefPubMed
50.
Zurück zum Zitat Bonvalot S, Muret J, Debaere T, et al. High response rates with isolated pelvic perfusion (IPP) with a pneumatic anti-shock garments (PASG) and low-dose TNF-α for locally advanced pelvic sarcomas and carcinomas: a phase II unicenter trial (abstract 10586). J Clin Oncol. 2008;26(Suppl). Bonvalot S, Muret J, Debaere T, et al. High response rates with isolated pelvic perfusion (IPP) with a pneumatic anti-shock garments (PASG) and low-dose TNF-α for locally advanced pelvic sarcomas and carcinomas: a phase II unicenter trial (abstract 10586). J Clin Oncol. 2008;26(Suppl).
Metadaten
Titel
Hyperthermic Isolated Limb Perfusion in Locally Advanced Soft Tissue Sarcoma and Progressive Desmoid-Type Fibromatosis with TNF 1 mg and Melphalan (T1-M HILP) Is Safe and Efficient
verfasst von
Sylvie Bonvalot, MD, PhD
Françoise Rimareix, MD
Sylvain Causeret, MD
Cécile Le Péchoux, MD
Bérénice Boulet, MD
Philippe Terrier, MD
Axel Le Cesne, MD
Jane Muret, MD
Publikationsdatum
01.12.2009
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2009
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0733-9

Weitere Artikel der Ausgabe 12/2009

Annals of Surgical Oncology 12/2009 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.